SM
KYNB

SG3 Management’s Kyntra Bio KYNB Stock Holding History

SG3 Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,800
Closed -$1.2M – 1074
2021
Q2 		$1.2M Buy
1,800
+120
+7% +$69.1K 0.04% 426
2021
Q1 		$1.46M Buy
1,680
+1,300
+342% +$1.38M 0.04% 498
2020
Q4 		$352K Buy
380
+200
+111% +$210K 0.01% 789
2020
Q3 		$185K Buy
+180
New +$194K 0.01% 737

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

SG3 Management's KYNB Position: Q1 2021 in Review

SG3 Management sold out of Kyntra Bio (KYNB) in Q1 2021, closing a stake of 140 shares — an estimated $149K sold.

SG3 Management first reported a position in KYNB in Q3 2020 and held it in 2 quarters. The position peaked at $206K in Q3 2020. 198 funds tracked by Wall St. Rank hold KYNB as of Q1 2021.

  • SG3 Management reported no remaining Kyntra Bio position as of Q1 2021 after selling out during the quarter.
  • SG3 Management sold 140 Kyntra Bio shares in Q1 2021, an estimated $149K.
  • SG3 Management first reported a position in Kyntra Bio in Q3 2020 and held it in 2 quarters.
  • SG3 Management's Kyntra Bio position peaked at $206K in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2021.

Based on SG3 Management's 13F filing for Q1 2021, filed 17 May 2021.